Clover Health reported strong membership and revenue growth, sustained adjusted EBITDA profitability, and operational efficiencies. However, challenges such as elevated utilization in Part D and supplemental benefits and industry-wide cost trends pose some concerns. Despite these challenges, the overall performance and strategic initiatives provide a positive outlook.

Company Guidance -

Q3 2025

During the Clover Health Second Quarter 2025 Earnings Call, CEO Andrew Toy highlighted the company's strategic plans and performance metrics. Clover Health achieved a 32% year-over-year increase in Medicare Advantage membership, reaching over 106,000 members, and a 34% rise in insurance revenue to $470 million in the second quarter. The company's adjusted EBITDA and adjusted net income remained steady at $43 million and $42 million, respectively, despite industry-wide pressures. Clover Health surpassed its adjusted EBITDA profitability target in 2024 and is on track to maintain this profitability throughout 2025. The company also expects to benefit from a 4-star payment year in 2026, further accelerating growth and profitability. Additionally, the use of Clover Assistant technology was correlated with a reduction in hospitalizations and readmissions for chronic obstructive pulmonary disease, demonstrating the real-world impact of their technology-first care model. The focus remains on leveraging technology to manage costs and deliver value, with anticipation for continued growth and financial strength in the upcoming years.

Sustained Adjusted EBITDA Profitability

Clover Health achieved sustained adjusted EBITDA profitability for the first half of 2025, following their profitability target in 2024, demonstrating their ability to maintain profitability alongside membership and revenue growth.

Significant Membership and Revenue Growth

Clover Health reported a 32% year-over-year increase in Medicare Advantage membership, reaching over 106,000 members, and a 34% increase in insurance revenue to $470 million in Q2 2025.

Improved SG&A Efficiency

The company improved its adjusted SG&A as a percentage of total revenues by 280 basis points year-over-year, showing operating leverage amidst strong growth.

Clinical Impact of Clover Assistant

A clinical white paper on COPD showed a relationship with the Clover Assistant provider correlated with 15% fewer hospitalizations and 18% fewer readmissions, highlighting the effectiveness of Clover’s technology-first care model.

Clover Health Investments (CLOV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLOV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.04 / -	-0.02	―	―	―
Aug 05, 2025	2025 (Q2)	>-0.01 / -0.02	0.01	-300.00% (-0.03)
May 06, 2025	2025 (Q1)	-0.04 / 0.05	-0.05	206.00% (+0.10)
Feb 27, 2025	2024 (Q4)	-0.07 / -0.04	-0.146	72.60% (+0.11)
Nov 06, 2024	2024 (Q3)	-0.04 / -0.02	-0.086	76.74% (+0.07)
Aug 05, 2024	2024 (Q2)	-0.05 / 0.01	-0.06	116.67% (+0.07)
May 07, 2024	2024 (Q1)	-0.07 / -0.05	-0.152	67.11% (+0.10)
Mar 12, 2024	2023 (Q4)	-0.14 / -0.15	-0.176	17.05% (+0.03)
Nov 06, 2023	2023 (Q3)	-0.11 / -0.09	-0.158	45.57% (+0.07)
Aug 08, 2023	2023 (Q2)	-0.14 / -0.06	-0.219	72.60% (+0.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLOV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$2.85	$2.26	-20.70%
May 06, 2025	$3.35	$3.77	+12.54%
Feb 27, 2025	$4.14	$3.97	-4.11%
Nov 06, 2024	$4.35	$3.67	-15.63%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.